NCT02329301View on ClinicalTrials.gov

Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

NACompletedINTERVENTIONAL
Enrollment

2,430

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2020

Conditions
MalariaMalaria, Falciparum
Interventions
DRUG

MDA with DHAp (Eurartesim)

Eurartesim is the brand name.

DRUG

Focal MDA with DHAp (Eurartesim)

Eurartesim is the brand name.

Trial Locations (1)

Unknown

Southern province medical office, Choma

All Listed Sponsors
collaborator

Ministry of Health, Zambia

OTHER_GOV

collaborator

Minister of Community Development, Mother and Child Health, Zambia

OTHER

collaborator

Tulane University

OTHER

lead

PATH

OTHER

NCT02329301 - Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia | Biotech Hunter | Biotech Hunter